Empowering Consumers to make Safer Buying Decisions : nonClonableID Technologies

With breakthrough research and development in nanotechnology and an emphasis on creating a cost-effective solution, Bilcare has created a first-of-its-kind nonClonableID™ Authentication Technology. Bilcare Technologies is a comprehensive response to counterfeiting and an indispensable tool for building confidence in consumers. Find out how our unique technology provides an increased degree of security and empowers consumers to authenticate a product in real-time.

nonClonableID Technologies

Bilcare Technologies is a research and technology leader focused on creating next-generation anti-counterfeiting, security and brand protection solutions for a broad range of industry sectors.

Bilcare Technologies is a business unit of Bilcare Ltd. - an innovation-led solutions provider that partners with the global pharmaceutical and healthcare industry to improve patient healthcare outcomes.

With breakthrough research and development in micro and nanotechnology, Bilcare Technologies has developed a first-of-its-kind technology - nonClonableID™. The solution enables products to be authenticated as they move through the supply chain to the end consumer.

India, Bilcare Technologies combines its innovative approach with in-depth business knowledge in brand protection and supply chain integrity to offer solutions tailored to varying client requirements.

We are firmly committed to helping our clients accomplish their business goals while protecting their brands against counterfeiting. With its affordability, security and ease of use, nonClonableID™ is a potent tool for the global economy in its fight against counterfeiting.

About nonClonableID

Bilcare’s nonClonableID™ comprises of a unique fingerprint that can be seamlessly integrated with products, ID cards and documents to provide a totally secure and reliable identification and authentication solution.

nonClonableID™ employs unique materials-based fingerprints that are prohibitively difficult to copy. These tamper-evident fingerprints are irreproducible and cannot be duplicated even by Bilcare.

Features of nonClonableID™

• Unique fingerprints generated out of randomly distributed micro and nano particles
• Machine-readable fingerprints enable an objective and reliable authentication process
• Real-time authentication through hand-held portable readers
• Fingerprints can be integrated with overt systems like barcodes/ RFID tags etc. and within any existing software/hardware infrastructure
• Proprietary scanning device scans the fingerprint and instantly communicates the encrypted information with a secure server through mobility platforms such as GPRS, 3G or Broadband.
• Complete authentication report on a mobile or computer using robust web enterprise secured applications and data management at back-end.

Bilcare GCS Expands Pre-Clinical and Early-Stage Development Capabilities

PHOENIXVILLE, Pa — November, 2008 — In its endeavor to accelerate the development process cycle resulting in enhanced “Speed to Market” for its clients, Bilcare Global Clinical Supplies, a leading single-source provider of Clinical Trial Supplies and services, endorses its continual capability enhancement commitment by supplementing its ability of developing functionally viable and innovative formulation dosage forms for pre-clinical and early-phase drugs.

Vincent Santa Maria, President – Bilcare GCS, Americas stated that as part of a major capital investment program at its facilities in the U.S., Bilcare GCS has added sophisticated fluid bed granulation and enhanced capsule filling technologies to its R&D Center. “With this upgrade, Bilcare GCS can now quickly produce a wider variety of drug dosage forms with high product quality at par industry benchmark. These investments in R&D services further prove our commitment to being a full-service partner to our global customers with the offering of a wide breath of specialty services, continues Vincent.”

This capability enhancement compliments the increasing number of investigational new drug (IND) applications by innovator pharma and Biotech companies, which in turn requires multi-pronged expertise, more particularly in the Formulation and Analytical research and development, commented Praful Naik, Ph.D., Chief Scientific Officer, Bilcare Limited.

The fluid-bed granulation technology extends Bilcare’s solid dosage formulation capabilities. The granulation system equipped with Wurster coating inserts enables Bilcare to develop and deliver specialized coating processes for granules and non-pareils with high precision and consistency for creation of top quality sustained and controlled-release tablet and capsule formulations.

The In-Cap® capsule system, capable of filling several thousand capsules per hour in multiple permutations, is a versatile tool for pre-clinical and early-stage development. This equipment extends both development and clinical manufacturing capabilities for a myriad of formulation types including powders, pellets, tablets and liquids.

“Bilcare’s R&D center can now develop a broad array of dosage forms with innovative delivery mechanisms, which exceeds those developed by pharmaceutical companies,” says Frank Santillo, Ph.D., Bilcare GCS’ senior director for research services. “Most importantly, we have the expertise to take a drug candidate from concept to clinical production without the client suffering critical and costly delays as a result of hand-offs, continues Frank”

About Bilcare Global Clinical Supplies

Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services, and complete project management. Its services for solid, semi-solid, liquid, DEA (CI-V), and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, manufacturing, analytical services and clinical supplies packaging and labeling, to IVRS, QP services, controlled temperature (cold chain) CTM storage, worldwide distribution, and returns and destructions accountability.